Atezolizumab for untreated PD-L1 positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (CDF review TA492) (ID3777)

£328.1K GBP

Funder	National Institute for Health Research
Recipient Organization	University of Southampton
Country	United Kingdom
Start Date	May 18, 2021
End Date	Aug 12, 2021
Duration	86 days
Number of Grantees	1
Roles	Award Holder
Data Source	Europe PMC
Grant ID	`NIHR131842`

Grant Description

To appraise the clinical and cost effectiveness of atezolizumab within its marketing authorisation for treating locally advanced or metastatic urothelial carcinoma in people who are considered cisplatin ineligible and whose tumours have a PD-L1 expression of 5% or more.